ArticleThe American journal of gastroenterology2015
Plasma cathepsin D levels: a novel tool to predict pediatric hepatic inflammation.
Article in The American journal of gastroenterology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 49 citations in OpenAlex.
- Serum LEAP-2 as a Potential Biomarker for Hepatic Steatosis in Adolescents with Obesity and MASLD: A Cross-Sectional Study.Diagnostics (Basel, Switzerland) · 2025Article
- Inhibition of intracellular versus extracellular cathepsin D differentially alters the liver lipidome of mice with metabolic dysfunction-associated steatohepatitis.The FEBS journal · 2025Article
- Plasma cathepsin D as an early indicator of alcohol-related liver disease.JHEP reports : innovation in hepatology · 2024Article
- Noninvasive biomarkers in pediatric nonalcoholic fatty liver disease.World journal of hepatology · 2023Review
- Targeted Proteins Reveal Cathepsin D as a Novel Biomarker in Differentiating Hepatocellular Carcinoma from Cirrhosis and Other Liver CancersAsian Pacific journal of cancer prevention : APJCP · 2022Article
- Advance of Serum Biomarkers and Combined Diagnostic Panels in Nonalcoholic Fatty Liver Disease.Disease markers · 2022Review
- Efficacy of Weight Reduction on Pediatric Nonalcoholic Fatty Liver Disease: Opportunities to Improve Treatment Outcomes Through Pharmacotherapy.Frontiers in endocrinology · 2021Article
- [Diagnosis and therapeutic strategies for non-alcoholic fatty liver disease in children].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2020Review
- Plasma cathepsin D activity is negatively associated with hepatic insulin sensitivity in overweight and obese humans.Diabetologia · 2020Article
- Plasma Cathepsin D Activity Rather Than Levels Correlates With Metabolic Parameters of Type 2 Diabetes in Male Individuals.Frontiers in endocrinology · 2020Article
- Nonalcoholic Fatty Liver Disease: An Update on the Diagnosis.Gene expression · 2019Review
- Limited applicability of cathepsin D for the diagnosis and monitoring of non-alcoholic steatohepatitis.JGH open : an open access journal of gastroenterology and hepatology · 2019Article
- Association between Lysosomal Dysfunction and Obesity-Related Pathology: A Key Knowledge to Prevent Metabolic Syndrome.International journal of molecular sciences · 2019Review
- Inhibiting Extracellular Cathepsin D Reduces Hepatic Steatosis in Sprague⁻Dawley RatsBiomolecules · 2019Article
- Update on pathogenesis, diagnostics and therapy of nonalcoholic fatty liver disease in children.Clinical and experimental hepatology · 2019Review
- Pediatric non-alcoholic fatty liver disease: current perspectives on diagnosis and management.Pediatric health, medicine and therapeutics · 2019Article
- Noninvasive biomarkers in NAFLD and NASH - current progress and future promise.Nature reviews. Gastroenterology & hepatology · 2018Review
- Cystatin B, cathepsin L and D related to surrogate markers for cardiovascular disease in children.PloS one · 2017Article
- Plasma cathepsin D correlates with histological classifications of fatty liver disease in adults and responds to intervention.Scientific reports · 2016Article
- Pediatric non-alcoholic fatty liver disease: Recent solutions, unresolved issues, and future research directions.World journal of gastroenterology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesNonalcoholic steatohepatitis (NASH) is the most severe form of a hepatic condition known as nonalcoholic fatty liver disease (NAFLD). NASH is histologically characterized by hepatic fat accumulation, inflammation, and ballooning, and eventually coupled with fibrosis that, in turn, may progress to end-stage liver disease even in young individuals. Hence, there is a critical need for specific noninvasive markers to predict hepatic inflammation at an early age. We investigated whether plasma levels of cathepsin D (CatD), a lysosomal protease, correlated with the severity of liver inflammation in pediatric NAFLD.
methodsLiver biopsies from children (n=96) with NAFLD were histologically evaluated according to the criteria of Kleiner (NAFLD activity score) and the Brunt's criteria. At the time of liver biopsy, blood was taken and levels of CatD, alanine aminotransferase (ALT), and cytokeratin-18 (CK-18) were measured in plasma.
resultsPlasma CatD levels were significantly lower in subjects with liver inflammation compared with steatotic subjects. Furthermore, we found that CatD levels were gradually reduced and corresponded with increasing severity of liver inflammation, steatosis, hepatocellular ballooning, and NAFLD activity score. CatD levels correlated with pediatric NAFLD disease progression better than ALT and CK-18. In particular, CatD showed a high diagnostic accuracy (area under receiver operating characteristic curve (ROC-AUC): 0.94) for the differentiation between steatosis and hepatic inflammation, and reached almost the maximum accuracy (ROC-AUC: 0.998) upon the addition of CK-18.
conclusionsPlasma CatD holds a high diagnostic value to distinguish pediatric patients with hepatic inflammation from children with steatosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.